

AD-A140 402


PLATELET SIZE AS A DETERMINANT OF PLATELET FUNCTION(U)  
BOSTON UNIV MA SCHOOL OF MEDICINE C B THOMPSON ET AL.  
10 MAR 83 BUSM-83-05 N00014-79-C-0168


1/1

UNCLASSIFIED

F/G 6/5

NL





MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS-1963-A

ADA140402

OFFICE OF NAVAL RESEARCH  
CONTRACT N00014-79-C-0168

12

TECHNICAL REPORT NO. 83-05

PLATELET SIZE AS A DETERMINANT OF PLATELET FUNCTION

by

C. B. THOMPSON, J. A. JAKUBOWSKI, P. G. QUINN, D. DEYKIN, AND C. R. VALERI

NAVAL BLOOD RESEARCH LABORATORY  
BOSTON UNIVERSITY SCHOOL OF MEDICINE  
615 ALBANY STREET  
BOSTON, MA 02118

10 March 1983

DTIC  
ELECTE  
APR 25 1984  
S D D

Reproduction in whole or in part is permitted for  
any purpose of the United States Government.

Distribution of this report is unlimited.

DTIC FILE COPY

84 04 20 018

## UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER NBRL, BUSM 83-05	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) PLATELET SIZE AS A DETERMINANT OF PLATELET FUNCTION		5. TYPE OF REPORT & PERIOD COVERED Technical Report
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Craig B. Thompson, Joseph A. Jakubowski,* Patrick G. Quinn, Daniel Deykin,* and C. Robert Valeri		8. CONTRACT OR GRANT NUMBER(s) N00014-79-C-0168
9. PERFORMING ORGANIZATION NAME AND ADDRESS Naval Blood Research Laboratory Boston University School of Medicine 615 Albany St., Boston, MA 02118		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
11. CONTROLLING OFFICE NAME AND ADDRESS Naval Medical Research and Development Command Bethesda, Maryland 20814		12. REPORT DATE 10 March 1983
		13. NUMBER OF PAGES 21
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) Bureau of Medicine and Surgery Department of the Navy Washington, D. C. 20372		15. SECURITY CLASS. (of this report) UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Approved for public release and sale. Distribution unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES *Department of Medicine, Veterans Administration Medical Center, Boston, MA		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Platelet size                      Platelet subpopulations Platelet function                  Elutriation Blood                                  Platelet aggregation Mean platelet volume              Dense bodies		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The relationship between mean platelet volume (MPV) and platelet function was studied in human platelet subpopulations separated on the basis of size by counterflow centrifugation. The original platelet population and five size-dependent platelet fractions were suspended in buffer or autologous PPP at a platelet count of $2 \times 10^8/\text{ml}$ . Collagen ( $10 \text{ ug/ml}$ ) induced aggregation showed a significant negative correlation between MPB and onset of aggregation and positive correlations between the MPB and the rate and extent of aggregation. Thrombin stimulation ( $1 \text{ U/ml}$ ) demonstrated similar relationships between MPV		

DD FORM 1473  
1 JAN 73EDITION OF 1 NOV 68 IS OBSOLETE  
S/N 0102-LF-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

and the rate and extent of aggregation. In contrast, ristocetin-induced platelet agglutination occurred at a similar rate and extent in all fractions. To quantitate further the differential response of the platelets we measured the content and release of ATP and B-thromboglobulin (B-TG). There was a significant correlation between MPV and both ATP and B-TG content and a progressive increase in the absolute release of ATP and B-TG associated with the increase in MPV after stimulation. However, the percent release of total ATP and B-TG was similar in all fractions. Our data indicate that the intrinsic function of platelets of different sizes is similar, but the absolute ability of platelets to affect their environment as measured by aggregation and total release of granular content is proportional to their size.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

## ABSTRACT

The relationship between mean platelet volume (MPV) and platelet function was studied in human platelet subpopulations separated on the basis of size by counterflow centrifugation. The original plate population and five size-dependent platelet fractions were suspended in buffer or autologous PPP at a platelet count of  $2 \times 10^8$ /ml. Collagen-<sup>beta</sup>(10  $\mu$ g/ml) induced aggregation showed a significant negative correlation between MPV and onset of aggregation and positive correlations between the MPV and the rate and extent of aggregation. Thrombin stimulation (1 U/ml) demonstrated similar relationships between MPV and the rate and extent of aggregation. In contrast, ristocetin-induced platelet agglutination occurred at a similar rate and extent in all fractions. To quantitate further the differential response of the platelets we measured the content and release of ATP and <sup>beta</sup>-thromboglobulin (<sup>beta</sup>-TG). There was a significant correlation between MPV and both ATP and <sup>beta</sup>-TG content and a progressive increase in the absolute release of ATP and <sup>beta</sup>-TG associated with the increase in MPV after stimulation. However, the percent release of total ATP and <sup>beta</sup>-TG was similar in all fractions. Our data indicate that the intrinsic function of platelets of different sizes is similar, but the absolute ability of platelets to affect their environment as measured by aggregation and total release of granular content is proportional to their size.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A1	



**RUNNING TITLE: SIZE-DEPENDENT PLATELET FUNCTION**

**ABBREVIATIONS**

<b>MPV</b>	<b>Mean platelet volume</b>
<b>PPP</b>	<b>Platelet-poor plasma</b>
<b>ATP</b>	<b>Adenosine triphosphate</b>
<b><math>\beta</math>-TG</b>	<b><math>\beta</math>-Thromboglobulin</b>
<b>EGTA</b>	<b>Ethyleneglycol-bis-(<math>\beta</math>-aminoethyl ether) N,N'-tetraacetic acid</b>
<b>TCB</b>	<b>Tris-citrate-bicarbonate</b>
<b>BSA</b>	<b>Bovine serum albumin (fatty acid free)</b>
<b>% <math>\Delta</math>T</b>	<b>Percent change in light transmission</b>
<b>EDTA</b>	<b>Ethylenediamine tetraacetate acid disodium salt</b>
<b>DMSO</b>	<b>Dimethyl sulfoxide</b>
<b>ADP</b>	<b>Adenosine diphosphate</b>

## INTRODUCTION

Platelets are known to be heterogeneous with respect to size, density, function, metabolism and age (1-14). However, the causes and significance of this heterogeneity remain controversial. Recent advances in cell sizing have made one index of platelet heterogeneity, the platelet volume distribution, routinely available in most clinical laboratories (15-17). Despite the increasing availability of MPV measurements the relevance of platelet volume to platelet physiology and pathology remains to be established. A number of authors have reported an apparent correlation between the MPV and platelet aggregation (3,5,13,18-21), and several theories have been proposed to explain the positive correlation. Karpatkin (5) has suggested that different sized platelets are qualitatively different because they are of different ages. Penington and co-workers (9,10) suggest that platelet size variation arises from production in the bone marrow of platelets with different functional capacities. Alternatively, the intrinsic function of platelets of varying size may be similar and the differences in function may be quantitative ones, directly predictable from differences in size. These quantitative differences may be based on the physical properties of different sized particles as proposed recently by Holme and Murphy (22) or they may be based on metabolic capacities which correlate with differences in size. Another possibility is that the observed relationship between the MPV and in vitro tests of platelet function might reflect an artifact based on the effects of differing platelet size on the turbidometric measurement of platelet aggregation.

In this study we have examined the relationship between MPV and in vitro platelet aggregation and the release of dense body and  $\alpha$ -granule contents.



Using human platelet subpopulations separated on the basis of size by counterflow centrifugation, we have confirmed the correlation between platelet volume and in vitro activity and attempted to define the nature of the relationship.

## MATERIALS AND METHODS

### Blood collection and platelet isolation

Blood (42.5 ml) was obtained from healthy male laboratory personnel who had not taken any medication known to affect platelet function nor had donated blood within the previous 10 days. The method for isolation of platelets from whole blood has been described in detail (13) and was used without modification.

### Platelet subpopulations

The method for isolation of size-dependent platelet subpopulations by counterflow centrifugation has been described in detail previously (13). In brief, counterflow centrifugation opposes an outwardly-directed centrifugal force with an inwardly directed force generated by the flow of fluid through the centrifuge separation chamber. Cells of different size equilibrate at different positions in the chamber and can be removed from the centrifuge sequentially by increasing the rate of flow through the chamber. Separation is achieved on the basis of cell size and the effect of differing cell density is minimal (13).

In these experiments  $4-7 \times 10^9$  platelets were loaded into the chamber of the counterflow centrifuge and separated into 7 sequential fractions (13). The 7 fractions and a sample of the original unfractionated platelet suspension

were placed on ice for 10 min and EGTA (Sigma Chemical Co., St. Louis, MO) was added to a final concentration of 1 mM. The platelets were then sedimented by centrifugation at 2000 x g for 10 min. The supernatant buffer was aspirated and the platelets resuspended in either Tris-citrate-bicarbonate (TCB) buffer (23) or autologous citrated PPP. In order to obtain comparable quantities of platelets in all fractions for subsequent functional studies, the platelets in fractions 1 and 2 and fractions 6 and 7 were pooled. The platelet count in all of the final suspensions was adjusted to approximately  $2 \times 10^8$ /ml. BSA and  $\text{CaCl}_2$  were added to a final concentration of 0.05% and 3 mM respectively.

#### Platelet counting and sizing

Platelet counts were performed visually by phase microscopy and electronically using a Coulter ZBI Counter (Coulter Electronics, Hialeah, FL). Platelets were sized using the linear scale on a Coulter ZB Counter with an H4 channelyzer attachment (Coulter Electronics) and a 50/60 aperture electrode. Details of these procedures and calibration routines have been presented previously (13).

#### Platelet aggregation and ATP release

Platelet aggregation and simultaneous ATP release were measured in a Lumi-Aggregometer (Chronolog Corp., Havertown, PA). Four hundred  $\mu\text{l}$  of the platelet suspension to which 50  $\mu\text{l}$  of luciferin/luciferase reagent was added, were stirred at  $37^\circ\text{C}$  in a siliconized glass cuvette for 2 min prior to stimulation. Lyophilized luciferin/luciferase reagent (Dupont Chemical Co., Wilmington, DE) was reconstituted to 50 mg/ml in 100 mM tris-HCl, pH 7.4

containing 54 mM  $\text{MgSO}_4$ . To control for differences in the optical density of the platelet subpopulations, each sample was adjusted to a baseline that set the optical density of the platelets in suspension at 10% light transmission. A blank of TCB buffer or PPP was set at 90% light transmission. Platelets were then stimulated with 50  $\mu\text{l}$  of either human  $\alpha$ -thrombin (Dr. John Fenton, New York State Department of Health), collagen (Hormon-Chemie, Munich, West Germany), or ristocetin A (Aggreclin, Bio/Data Corp., Horsham, PA). Aggregation was measured as the percent change in light transmission (%  $\Delta\text{T}$ ) over time. ATP release was measured as maximum generation of luminescence (24).

#### Validation of turbidometric measurements of aggregation

Platelet aggregates were fixed with 50  $\mu\text{l}$  of 0.1 M EDTA in 2.5% formalin (25) at 20%  $\Delta\text{T}$  or after maximum %  $\Delta\text{T}$  (typically 5 min). Aggregometer readings confirmed that this addition arrested aggregation and deaggregation almost instantaneously leaving the light transmission of the sample stable for at least 10 min. Aggregates were then removed by a modification of the method of Haver and Gear (21) by centrifuging the sample at 500 x g for 10 sec on a Sorvall GLC-2 centrifuge. A control platelet suspension to which 50  $\mu\text{l}$  of buffer was added instead of aggregating agent, was centrifuged simultaneously. After centrifugation, 400  $\mu\text{l}$  of supernate from both the aggregated sample and the control were removed and counted for the number of residual single platelets. The percent of platelets remaining unaggregated was determined by dividing the platelet count in the aggregated sample by the count in the control. Each sample was processed in duplicate and the mean used for data analysis.

#### Quantitation of ATP content and release

ATP content was measured by solubilization of a stirred mixture of 400  $\mu$ l of platelet suspension and 50  $\mu$ l of luciferin/luciferase reagent with 50  $\mu$ l of 10% Triton X-100 (Sigma) in the Lumi-Aggregometer. The luminescence generated was measured and ATP concentration calculated from a standard curve obtained by adding known amounts of an ATP standard to an analogous cell-free system. The maximum release of ATP from platelets during platelet aggregation was measured as above in the Lumi-Aggregometer and converted to concentrations by use of the standard curve. In control experiments the presence of Triton X-100 was shown to have no significant effect on luminescence generated by the addition of ATP.

#### $\beta$ -Thromboglobulin content and release

Samples prepared for ATP release as described above were removed from the Lumi-Aggregometer after 5 min and transferred to an Eppendorf microcentrifuge tube containing 50  $\mu$ l of ice-cold 10% DMSO in 200 mM EDTA (26). The sample was immediately centrifuged at 12,000  $\times$  g for 4 min in an Eppendorf Model 5412 Microcentrifuge. Four hundred  $\mu$ l of the resulting supernate were removed, stored at  $-20^{\circ}\text{C}$  and subsequently assayed for  $\beta$ -thromboglobulin by radioimmunoassay using a commercially available kit (Amersham Corp., Arlington Heights, IL). Total  $\beta$ -TG content was measured in tritonized samples, prepared as described above for total ATP content. Prior to assay the samples were diluted 100-fold with TCB buffer and the  $\beta$ -TG standards were reconstituted in TCB buffer. In preliminary experiments it was determined that the levels of luciferin/luciferase reagent, DMSO/EDTA, and Triton X-100 present had no effect on the standard curve. All radioimmunoassays were performed in duplicate and results calculated from the mean.

### Statistics

Statistical evaluation of data was performed by linear regression analysis (27).

### RESULTS

The characteristics of the size-dependent platelet subpopulations used in the functional studies are given in Table 1. Increasing fraction number corresponds closely to increasing fraction MPV and total recovery through the counterflow centrifuge was  $91.8 \pm 5.6\%$  (mean  $\pm$  SD,  $n = 10$ ). Each of the 5 subpopulations contained between  $16.8 \pm 4.3\%$  and  $23.4 \pm 1.2\%$  of the recovered platelets. The ATP and  $\beta$ -TG content per  $10^8$  platelets from each subpopulation show a close correlation ( $p < 0.001$ ,  $p < 0.01$  respectively) with the MPV of the platelets (Table 1). No significant differences were seen in the platelet counts after resuspension in TCB buffer prior to aggregation studies. During all procedures the original unfractionated platelet population was also studied. The values for the unfractionated platelets were generally in the mid-range of the fractions' value.

Fig. 1 shows typical aggregation responses of the platelet subpopulations and original unfractionated platelets to stimulation with collagen (10  $\mu$ g/ml) and thrombin (1 U/ml). These concentrations best illustrate the differential aggregation between fractions. However, the large platelets would routinely respond to smaller stimuli (0.25 U/ml thrombin, 2.5  $\mu$ g/ml collagen) but the response of smaller platelets was undetectable (results not shown). Aggregation was quantitated by measurement of lag time (time from addition of aggregating agent to onset of aggregation), initial rate of aggregation (slope of the initial % AT after onset of aggregation), and maximal aggregation (maximum % AT after 5 min). The results of these measurements for

collagen-induced aggregation at final concentrations of 10 and 50  $\mu\text{g/ml}$  are shown in Fig. 2a. For both concentrations there is a significant inverse correlation between the lag time and the MPV of the fraction ( $p < 0.01$ ), while both the initial rate and the extent of aggregation showed significant positive correlations ( $p < 0.05$ ,  $p < 0.01$  respectively). Fig. 2b shows equivalent data for three different thrombin concentrations (0.25, 0.5, and 1.0 U/ml). As with collagen, for all three thrombin concentrations, there is a significant positive correlation between both rate ( $p < 0.001$ ) and extent ( $p < 0.05$ ) of aggregation and the MPV of the platelet subpopulations. The lag time for thrombin-induced aggregation was much shorter than for collagen-induced aggregation and in contrast to collagen, while there was a decrease in lag time with increasing thrombin dose, no significant differences in lag time were noted between the fractions at any given dose. The patterns observed in Fig. 2 were seen consistently in each individual experiment. Values for unfractionated platelets and their representative standard deviations are shown on the side of each figure.

To correlate the results of collagen- and thrombin-induced aggregation as measured by the aggregometer with effects on single platelets, aggregation was arrested at two different points using EDTA/formalin (Table 2). In the first experiments, aggregation was arrested when each of the platelet fractions exhibited 20% AT and the number of single platelets remaining was determined. At the same extent of aggregation, as measured by the aggregometer, approximately the same number of platelets were left unaggregated in each fraction ( $p > 0.1$ ). After 5 min collagen-induced aggregation was complete (Fig. 1), at this time the number of single platelets remaining unaggregated becomes progressively less with increasing fraction size ( $p < 0.05$ ). Both platelet counting

and aggregometry reveal the same trend of progressively greater aggregation with increasing fraction MPV. Similar data to that reported for collagen-induced aggregation were obtained with 1 U/ml thrombin (data not shown).

To test the possibility that the observed differences in aggregation reflected physical differences in size, ristocetin-induced agglutination of each of the subpopulations was measured. A dose response curve of the unfractionated platelets was performed and a dose in the mid-range of the agglutination response was chosen for study. Lack of ATP release verified that we were observing only agglutination and not the combined effects of agglutination and secondary platelet aggregation. In a series of three experiments, no difference in the rate or extent of aggregation was seen between the unfractionated platelets and any of the subpopulations. The results of a representative experiment are shown in Fig. 3. To ensure that the concentration of von Willebrand factor was not limiting, the experiments were performed on subpopulations resuspended in autologous PPP. Collagen-induced aggregation of the same plasma resuspended platelets showed the same patterns of response as those in Fig. 1.

ATP release was measured during collagen- and thrombin-induced aggregation (Fig. 4). For each dose of collagen and thrombin there was positive correlation ( $p < 0.01$ ) between the MPV of the fraction and the absolute quantity of ATP released. However, the larger platelets had a greater initial ATP content (Fig. 1). To correct for this the data have been presented in the lower graphs as the percent of total ATP content released. When the data were expressed in this way no significant difference was seen in the ability of the platelets to release ATP in response to a given dose of either collagen or thrombin ( $p > 0.1$ ).

The release of  $\beta$ -TG was also measured after thrombin- (1 U/ml) or collagen- (10  $\mu$ g/ml) induced aggregation (Fig. 5). There was a positive correlation ( $p < 0.05$ ) between the MPV and the absolute quantity of  $\beta$ -TG released. When release was expressed as a percent of the original  $\beta$ -TG content, the percent release from all the fractions was similar ( $p > 0.5$ ).

### DISCUSSION

Our results demonstrate a significant correlation between platelet volume and in vitro tests of platelet function. For both collagen- and thrombin-induced platelet aggregation increasing rate and extent of response were noted with increasing MPV of the fractions and the validity of these observations was confirmed by serial platelet counts. Holme and Murphy (22) have recently suggested that large platelets might aggregate more quickly than small ones merely because they collide with each other more frequently. However, in the present study agglutination of size-dependent platelet subpopulations by ristocetin showed no differences in the rate or extent of response between the fractions. Since in the absence of platelet activation (indicated by the absence of the release reaction during ristocetin-induced agglutination), no difference in the response patterns of the platelet subpopulations was observed, differences in aggregation patterns cannot simply reflect physical differences in size of the platelet subpopulations. Thus the differential response of the platelets represents differences in the platelets' functional ability to respond to the different aggregating agents.

One mechanism by which platelets promote aggregation is through the release reaction. By releasing aggregatory agents such as ADP and thromboxane



A<sub>2</sub> platelets can catalyze their own reactions since concentrations of different aggregating agents appear to be additive in their effects on platelet aggregation (28). To study the relationship between the MPV and the release reaction, ATP, a dense body constituent, and  $\beta$ -TG, an  $\alpha$ -granule constituent, were measured during collagen- and thrombin-induced platelet aggregation. Large platelets contained proportionately larger amounts of ATP and  $\beta$ -TG than smaller ones. The differential aggregation response of the subpopulations could reflect different thresholds for the induction of the release reaction which is a qualitative difference. However, the percent release of both ATP and  $\beta$ -TG was the same in all fractions when tested over a range of thrombin and collagen doses. Alternatively, the larger platelets could exhibit an enhanced aggregation response by virtue of releasing greater absolute quantities of aggregatory substances, a qualitative difference. This study demonstrated an increased absolute release of both ATP and  $\beta$ -TG proportional to the increase in platelet size.

Platelet arachidonic acid metabolites are also important modulators of platelet activity and their role in the differential response of size-dependent platelet subpopulations is currently under investigation.

Our data indicate that the intrinsic function of size-dependent platelet subpopulations is similar but the absolute ability of platelets to affect each other and their environment as measured by aggregation and the release reaction respectively is proportional to their size.

REFERENCES

1. Corash L, Tan H, and Gralnick HR: Heterogeneity of human whole blood platelet subpopulations. I. Relationship between bouyant density, cell volume, and ultrastructure. *Blood* 49:71, 1977.
2. Corash L, Shafer B, and Perlow M: Heterogeneity of human whole blood platelet subpopulations. II. Use of a subhuman primate model to analyze the relationship between density and platelet age. *Blood* 52:726, 1978.
3. Ginsburg AD and Aster RH: Changes associated with platelet aging. *Thromb Diath Haemorrh* 27:407, 1972.
4. Karpatkin S: Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. *J Clin Invest* 48:1073, 1969.
5. Karpatkin S: Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. *J Clin Invest* 48:1083, 1969.
6. Mezzano D, Hwang K, Catalano P, and Aster RH: Evidence that platelet bouyant density, but not size, correlates with platelet age in man. *Am J Hematol* 11:61, 1981.
7. Minter FM and Ingram M: Platelet volume: density relationships in normal and acutely bled dogs. *Br J Haematol* 20:55, 1971.
8. Paulus JM: Platelet size in man. *Blood* 46:321, 1975.
9. Penington DG, Lee NLY, Roxburgh AE, and McGready JR: Platelet density and size: The interpretation of heterogeneity. *Br J Haematol* 34:365, 1976.
10. Penington DG, Sreatfield K, and Roxburgh AE: Megakaryocytes and the heterogeneity of circulating platelets. *Br J Haematol* 34:639, 1976.

11. Rand ML, Greenberg JP, Packham MA, and Mustard JF: Density subpopulations of rabbit platelets: Size, protein, and sialic acid content, and specific radioactivity changes following labeling with  $^{35}\text{S}$ -sulfate in vivo. *Blood* 57:741, 1981.
12. Shaw T, Martin JF, Chesterman CN, and Penington DG: The density distribution of intact platelets following their isolation from all other blood constituents. *Thromb Haemost* 46:409, 1981.
13. Thompson CB, Eaton KA, Princiotta SM, Rushin CA, and Valeri CR: Size-dependent platelet subpopulations: Relationship of platelet volume to ultrastructure, enzymatic activity, and function. *Br J Haematol* (in press).
14. Vainer H: The platelet populations. *Adv Exp Med Biol* 34:191, 1972.
15. Rowan RM, Fraser C, Gray JH, and McDonald GA: The Coulter Counter Model S-Plus: The shape of things to come. *Clin Lab Haematol* 1:29, 1979.
16. Giles C: The platelet count and mean platelet volume. *Br J Haematol* 48:31, 1981.
17. Bessman JD, Williams LJ, and Gilmer PR: Mean platelet volume. The inverse relationship of platelet size and count in normal subjects, and an artifact of other particles. *Am J Clin Path* 76:289, 1981.
18. Manucci PM and Sharp AA: Platelet volume and shape in relation to aggregation and adhesion. *Br J Haematol* 13:608, 1967.
19. Karpatkin S: Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. *Blood* 51:367, 1978.
20. Goldschmidt B and Sorland SJ: The young platelet population in children with cyanotic congenital heart disease. *Thromb Haemost* 35:342, 1976.

21. Haver VM and Gear ARL: Functional fractionation of platelets. *J Lab Clin Med* 97:187, 1981.
22. Holme S and Murphy S: Influence of platelet count and size on aggregation studies. *J Lab Clin Med* 97:623, 1981.
23. Rittenhouse-Simmons S and Deykin D: Isolation of membranes from normal and thrombin-treated gel-filtered platelets using a lectin marker. *Biochim Biophys Acta* 426:688, 1976.
24. Feinman RD, Lubowsky J, Charo I, and Zabinski M: The lumi-aggregometer: A new instrument for simultaneous measurement of secretion and aggregation by platelets. *J Lab Clin Med* 90:125, 1977.
25. Wu KK and Hoak JC: A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. *Lancet* 2:924, 1974.
26. Russell FA and Deykin D: The use of high pressure liquid chromatography (HPLC) for the separation of radiolabeled arachidonic acid and its metabolites produced by thrombin-treated human platelets. I. The validation of the technique. *Prostaglandins* 18:11, 1979.
27. Kleinbaum DG and Kupper LL: Applied regression analysis and other multi-variable methods. North Scituate 1978, Duxbury Press, p 50.
28. Huang EM and Detwiler TC: Characteristics of the synergistic actions of platelet agonists. *Blood* 57:685, 1981.

TABLE I

Characteristics of human size-dependent platelet subpopulations

FRACTION #	MPV ( $\mu^3$ , n=10)	% OF RECOVERED PLATELETS (n=10)	$\beta$ -TG ( $\mu\text{g}/10^8$ plt., n=6)	ATP (nmoles/ $10^8$ plt., n=7)
1/2	$4.34 \pm 0.39$	$19.5 \pm 5.6$	$3.05 \pm 0.91$	$1.54 \pm 0.50$
3	$5.34 \pm 0.46$	$19.4 \pm 2.7$	$4.58 \pm 0.77$	$1.89 \pm 0.61$
4	$6.32 \pm 0.50$	$23.4 \pm 1.2$	$5.90 \pm 1.14$	$2.41 \pm 0.70$
5	$7.24 \pm 0.57$	$20.9 \pm 3.5$	$7.99 \pm 1.73$	$3.11 \pm 1.09$
6/7	$7.89 \pm 0.59$	$16.8 \pm 4.3$	$10.99 \pm 2.07$	$3.79 \pm 1.05$
Unfractionated	$6.69 \pm 0.54$	----	$6.43 \pm 1.59$	$2.74 \pm 0.87$

Results expressed as mean  $\pm$  SD


TABLE 2

Percent of single platelets remaining after partial and complete aggregation

Fraction #	Aggregation inhibited at:	
	20% $\Delta T$	5 min
1/2	59.2 $\pm$ 6.7	23.5 $\pm$ 5.4
3	59.9 $\pm$ 5.4	14.0 $\pm$ 5.0
4	57.0 $\pm$ 8.6	12.3 $\pm$ 4.3
5	57.4 $\pm$ 5.8	10.9 $\pm$ 6.3
6/7	52.3 $\pm$ 3.6	10.4 $\pm$ 5.3
Unfractionated	62.0 $\pm$ 9.7	12.8 $\pm$ 3.0


Aggregation was induced by collagen (10  $\mu$ g/ml) and aggregates fixed by the addition of formalin-EDTA after 20% change in light transmission or after complete aggregation at 5 min (mean  $\pm$  SD, n = 3).

FIGURE 1



Collagen- and thrombin-induced aggregation of size-dependent platelet subpopulations and original unfractionated platelets. The platelet count in each fraction was  $2 \times 10^8$ /ml and each figure is representative of at least four experiments.

FIGURE 2a




Collagen-induced aggregation of size-dependent platelet subpopulations.

—○— 10 ug/ml collagen (mean,  $n = 4$ ). ○ Unfractionated platelets (mean  $\pm$  SD).

—△— 50 ug/ml collagen (mean,  $n = 4$ ). △ Unfractionated platelets (mean  $\pm$  SD).




FIGURE 2b



Thrombin-induced aggregation of size-dependent platelet subpopulations.


- 0.25 U/ml thrombin (mean,  $n = 3$ ). ○ Unfractionated platelets (mean  $\pm$  SD).
- △— 0.5 U/ml thrombin (mean,  $n = 4$ ). △ Unfractionated platelets (mean  $\pm$  SD).
- 1.0 U/ml thrombin (mean,  $n = 5$ ). □ Unfractionated platelets (mean  $\pm$  SD).

FIGURE 3



Ristocetin-induced agglutination of size-dependent platelet subpopulations and original unfractionated platelets. The platelet count in each fraction was  $2 \times 10^8$ /ml and the figure is representative of three experiments.

FIGURE 4



Collagen-induced ATP release.

—○— 10  $\mu$ g/ml (mean,  $n = 4$ ).

—△— 50  $\mu$ g/ml (mean,  $n = 5$ ).

┌ Unfractionated platelets  
(mean  $\pm$  SD)

Thrombin-induced ATP release.


—○— 0.25 U/ml (mean,  $n = 3$ )

—△— 0.5 U/ml (mean,  $n = 4$ ).

—□— 1.0 U/ml (mean,  $n = 5$ )

┌ Unfractionated platelets  
(mean  $\pm$  SD).

FIGURE 5



Collagen- and thrombin-induced  $\beta$ -TG release.

—○— 10  $\mu\text{g/ml}$  collagen (mean, n = 4).

—□— 1 U/ml thrombin (mean, n = 5).

○ Unfractionated platelets (mean  $\pm$  SD).

□ Unfractionated platelets (mean  $\pm$  SD).

END

FILMED

6-34

DTIC